두경부암 치료제 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Head and Neck Cancer Therapeutics Market was valued at USD 1.8 billion in 2023 and is projected to grow at a CAGR of 8.9% from 2024 to 2032. The primary driver of this market growth is the rising prevalence of head and neck cancer. Statistics from GLOBOCAN highlight head and neck cancer as one of the most prevalent cancers worldwide. Furthermore, the escalating consumption of tobacco and alcohol, both significant risk factors for head and neck cancers, is poised to further propel the industry growth.

As individuals age, their susceptibility to genetic mutations heightens, and the body's DNA repair mechanisms wane, amplifying cancer risks. This natural aging trajectory indicates that an expanding elderly demographic will likely see a surge in cancer cases. The American Cancer Society notes that approximately 57% of new cancer diagnoses and 75% of cancer-related deaths are in individuals aged 65 years and older. Notably, this age bracket is the fastest growing segment, especially in developed nations like the U.S.

The rising prevalence of head and neck cancer significantly propels the market. For instance, in 2024, the National Cancer Institute projects that 71,000 individuals in the U.S. will be diagnosed with cancers of the pharynx, larynx, or oral cavity. HPV, especially type 16, poses a notable risk for oropharyngeal cancers, particularly those impacting the tonsils and tongue's base. An uptick in HPV-related infections correlates with a rise in these cancers.

The overall industry is divided into therapy type, route of administration, distribution channel, and region.

The market segments by therapy type include chemotherapy, immunotherapy, targeted therapy, and others. In 2023, the immunotherapy segment led the market, accounting for USD 972.7 million. Immunotherapy emerges as a beacon of hope for head and neck cancer patients, especially those grappling with advanced or recurrent stages. By harnessing the body's immune system to identify and combat cancer cells, immunotherapy presents a compelling alternative to conventional treatments, such as surgery, radiation, and chemotherapy.

Routes of administration for head and neck cancer therapeutics include injectables, oral methods, and others. The injectables commanded a dominant 57.4% share in 2023. Leading immunotherapy agents for head and neck cancer, including Pembrolizumab (Keytruda) and Nivolumab (Opdivo), are primarily delivered via IV injectables. These agents target specific proteins on cancer or immune cells, necessitating direct bloodstream administration for optimal efficacy.

North America led the global head and neck cancer therapeutics market, generated USD 661.4 million in revenue in 2023 with projections to hit USD 1.4 billion by 2032. This regional leadership is attributed to a robust healthcare infrastructure and regulatory frameworks that fast-track the introduction and acceptance of innovative therapies. Furthermore, increased patient awareness coupled with access to cutting-edge treatment options cements North America's position in the industry landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of head and neck cancer
    • 3.2.1.2 Growing geriatric population base
    • 3.2.1.3 Rising investment in R&D to develop new drugs
    • 3.2.1.4 Supportive reimbursement policies and rising awareness about disease
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Chemotherapy
• 5.3 Immunotherapy
• 5.4 Targeted therapy
• 5.5 Other therapies

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Injectable
• 6.3 Oral
• 6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacy
• 7.3 Retail and specialty pharmacy
• 7.4 Online pharmacy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca plc
• 9.4 Bristol-Myers Squibb Company (BMS)
• 9.5 C.H. Boehringer Sohn AG and Co. KG
• 9.6 Clinigen Group plc.
• 9.7 Coherus BioSciences
• 9.8 Cumberland Pharmaceuticals, Inc.
• 9.9 Eli Lilly and Company
• 9.10 F. Hoffmann-La Roche Ltd.
• 9.11 GSK plc
• 9.12 Merck and Co., Inc.
• 9.13 Sanofi S.A.
• 9.14 Takeda Pharmaceutical Company Limited
• 9.15 Teva Pharmaceutical Industries Ltd.